Page 294 - Drug Class Review
P. 294
Page 177 of 205
Drug Effectiveness Review Project
placebo 74.0 58.3 100 0.71 17.3 Secondary Outcome Measures: MMSE; ADS; CGIC rated by caregivers Significantly more improvement on the CASI for TAC compared to placebo (P = 0.05)* No significant differences in patient or caregiver rated CGIC (P > 0.5)* No significant differences in IQCODE between TAC and placebo (P > 0.5)* Marginally significant improvement in MMSE for TAC-treated patients compared to placebo (P = No significant differences in ADS between TAC and placebo (P > 0.5)
Alzheimer classification: Mild-to-moderate
Groups similar at baseline: Yes
Health Outcome Measures: NR 0.057)
tacrine 73.6 48.6 100 0.66 15.8 Primary Outcome Measures: CASI; CGIC; IQCODE Timing of assessments: Baseline and every 6 weeks Intermediate Outcome Measures:
• • • • • •
Final Report Update 1 Authors: Wong et al. Year: 1999 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% Chinese): Other germane population qualities: Baseline HIS • Baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
